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Abstract 
Background: Use of statins has been associated with a reduced incidence of esophageal 
adenocarcinoma in population-based studies.  However there are few studies examining statin 
use and the development of Barrett’s esophagus. 
Aim: To examine the association between statin use and the presence of Barrett’s esophagus 
in patients having their first gastroscopy. 
Methods: We have performed a case-control study comparing statin use between patients 
with, and without, an incident diagnosis of non-dysplastic Barrett’s esophagus.  Male 
Barrett’s cases (134) were compared to 268 male age-matched controls in each of two control 
groups (erosive gastro-esophageal reflux and dyspepsia without significant upper 
gastrointestinal disease). Risk factor and drug exposure were established using standardised 
interviews. Logistic regression was used to compare statin exposure and correct for 
confounding factors. We performed a meta-analysis pooling our results with 3 other case-
control studies. 
Results: Regular statin use was associated with a significantly lower incidence of Barrett’s 
esophagus compared to the combined control groups (adjusted OR 0.62 (95% confidence 
intervals 0.37-0.93)). This effect was more marked in combined statin plus aspirin users 
(adjusted OR 0.43 (95% CI 0.21 – 0.89). The inverse association between statin or statin plus 
aspirin use and risk of Barrett’s was significantly greater with longer duration of use.  Meta-
analysis of pooled data (1098 Barrett’s, 2085 controls) showed that statin use was 
significantly associated with a reduced risk of Barrett’s esophagus (pooled adjusted OR 0.63 
(95% CI 0.51 - 0.77)  
Conclusions: Statin use is associated with a reduced incidence of a new diagnosis of 
Barrett’s esophagus.   
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Introduction 
There has been a dramatic increase in the incidence of esophageal adenocarcinoma (EAC) in 
the developed world (1,2). The reasons for the upsurge are unclear but increasing gastro-
esophageal reflux and the increasing prevalence of obesity are likely to be important. (3,4). It 
is accepted that metaplastic transformation of the esophageal squamous mucosa to intestinal-
type mucosa (Barrett’s esophagus (BE)) is a premalignant phenotype, although the overall 
rate of progression is relatively low (probably about 1 in 300 patients per year, or less)(5-7) 
and this has allowed the development of surveillance and localised treatment strategies such 
as radio-frequency ablation as means of preventing the development of EAC (8). However 
overall mortality from EAC remains considerable with 5-year survival less than 25% (9). 
One avenue that may offer some promise for both patients with known Barrett’s esophagus 
and the wider population is chemoprevention. Several lines of evidence suggest that statins 
(HMG-CoA reductase inhibitors) and cyclo-oxygenase (COX) inhibitors (especially low-dose 
aspirin) may have some utility in the chemoprevention of esophageal adenocarcinoma. In 
experimental studies statins and COX-2 inhibitors have useful anti-cancer effects. Statins 
inhibit proliferation, induce apoptosis and inhibit growth factor signalling in Barrett’s cell 
lines (10,11) and whilst COX-pathway inhibitors also have experimental anticancer effects, 
these are additive to those of statins (10-12). Several observational studies and two meta-
analyses (13-17) have reported that statin use is associated with a lower rate of progression to 
cancer in patients with Barrett’s oeosphagus and again this effect is significantly enhanced in 
combination with aspirin (16). In a meta-analysis, pooled adjusted odds ratios showed that 
statin use in the Barrett’s population was associated with a 43% reduction in the risk of 
malignant progression (OR = 0.57 (95% CI 0.43- 0.75)) and this effect was even more 
pronounced in those concurrently using low-dose aspirin (OR 0.26 (95% CI 0.1-0.68))(16). 
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Population-based studies have also shown that statin use is associated with a reduced 
incidence of esophageal adenocarcinoma, a 19% reduction in EAC was reported in a meta-
analysis (OR 0.81 (95% CI 0.75-0.88))(16). Subsequently a further large study using the UK 
General Practice Research Database reported that statin use in the general population was 
again associated with a reduced incidence of EAC (OR 0.58 (95% CI 0.39 – 0.87)(18). 
Therefore there are intriguing data that statins, particularly in combination with aspirin or 
other cyclooxygenase inhibitors may prevent the development of EAC. An important 
question is whether statins have actions in preventing the development and establishment of 
BE or whether they predominantly prevent malignant progression of BE. This question is 
important both for our understanding of the pathogenesis of BE and EAC but also in planning 
chemopreventative strategies. Therefore we have performed a case-control study to examine 
whether statin use is associated with a reduced incidence of Barrett’s esophagus.  
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Materials and Methods 
Cases and controls 
All cases and controls were recruited from patients under the care of the Gastroenterology 
Unit at the Norfolk and Norwich University Hospital. This is a large, public, secondary and 
tertiary referral hospital, serving a population of approximately 600 000. All patients gave 
written informed consent and the study was approved by the Norfolk Research Ethics 
Committee and the Norfolk and Norwich University Hospital Research Governance 
Committee.  
Controls and cases were recruited as part of a larger project examining risk and prognostic 
factors for gastrointestinal diseases (14,15,19). All subjects were planned to undergo their first 
ever gastroscopy. All subjects were interviewed by trained interviewers immediately preceding 
their endoscopy as previously reported (14,15,19). The standardised interview included 
demographic and social details, prescribed and over-the-counter medicine use. Medication use 
was regarded as positive if taken at least once per week for at least 6 months prior to the 
interview. Aspirin and non-aspirin NSAIDS were recorded separately. When subjects had 
taken more than one type or dose of a drug in any class, the usage was classified according the 
current dose regime. Results from the interviews were cross-referenced with clinical notes and 
letters (19).  In case of discrepancy in records of drug exposure, the patients’ description was 
used. Diagnostic endoscopy was performed by consultant gastroenterologists (111 subjects), 
accredited (141 subjects) - or consultant-supervised (53 subjects) trainees or accredited nurse-
endoscopists (97 subjects) with Olympus XQ240, XQ260 or XQ290 video-endoscopes.  
For the study, incident Barrett’s esophagus cases were included if they were having their first 
ever diagnostic gastroscopy during the study period and this demonstrated an endoscopic 
diagnosis of Barrett’s esophagus with at least 3 cm of Barrett’s epithelium visible and had 
intestinal metaplasia subsequently confirmed on histology.  Two Control groups, (i) erosive 
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gastro-esophageal reflux (“reflux”) and (ii) dyspepsia without erosive reflux (“dyspepsia”) 
were included and both were sex and age matched (within 5 years), 2 controls per case in each 
group from those attending for diagnostic gastroscopy for any symptoms. Controls were 
included in the reflux group if Los Angeles grade B-D changes were seen at endoscopy. 
Controls in the non-reflux group were those referred for investigation of upper GI symptoms 
without any subsequent significant endoscopic findings. Patients with either a Barrett’s 
segment < 3 cm in maximal length, or lacking intestinal metaplasia on histology, or Los 
Angeles A endoscopic changes were excluded from the study completely, in order to keep 
clarity to the cases and controls. Other exclusions were: evidence of dysplasia or neoplasia or 
anywhere in the upper GI tract, gastrodudoenal ulceration or an inability to complete the 
interview.  
 
 
Statistical analysis 
An initial minimal sample size of 127 Barrett’s cases and 254 of each of reflux-controls and 
non-reflux controls was planned to give 80% power to detect an odds ratio of 0.50 assuming 
a statin use prevalence of 35 % in controls. In this initial exploration of any potential effects 
of statins we planned to limit the study to males: both statin use and a new diagnosis of 
Barrett’s esophagus are less common in females and recruiting cohorts of suitable size 
(approximately 160 cases, 320 controls did not seem feasible). The exposure to statins and 
other medications of interest were compared against the control groups using a chi square 
statistic. The analyses were performed using SPSS for windows version 16.0 (IBM, 
Portsmouth, United Kingdom). The differences between the groups were quantified using the 
calculated odds ratios and 95% confidence intervals, with the significance level set at P < 
0.05. Unconditional logistic regression was used to correct for potentially confounding 
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factors: age, smoking, alcohol use, body mass index, waist circumference and all prescribed 
and over the counter mediations recorded (14,15,19).  
 
Meta-analysis 
The Pubmed, EMBASE, Cochrane Library, Web of Science and Wiley Interscience and  
Google Scholar databases were searched for relevant publications, published in English up to 
31/3/2015 using the search terms “Barrett’s esophagus,” esophagus,” “statin,” and 
“Hydroxymethyglutaryl-CoA reductase inhibitor.” The reference lists of these papers were 
then hand searched for any additional publications. Randomised controlled studies, case-
control studies and prospective cohort studies were eligible for inclusion. Meta-analysis was 
performed as previously described (16,20). 
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Results 
Baseline characteristics and confounding variables 
A total of 134 incident Barrett’s cases and 268 erosive-reflux and 268 dyspepsia controls 
were recruited. All subjects were white and of North West European origin, Participation was 
100% of those approached about the study.  The baseline characteristics of controls and cases 
are listed in table 1. All groups were reasonably well matched regarding basic demographic 
details, with no statistically significant differences, although rates of smoking, both current 
and previously, and body mass index and waist circumference tended to be higher in the 
Barrett’s group.  
 
Medication use and Barrett’s esophagus 
The results of medication used prior to enrolment in the study are shown in table 2.  All 
subjects taking a statin and aspirin were taking their medication daily and were taking the 
standard circulatory-protective dose of aspirin (75 mg daily). Unadjusted odds ratios for drug 
exposure showed a lower use statins in the Barrett’s oeosphagus group compared to both the 
dyspepsia group (OR 0.58 (95% confidence intervals (CI) 0.38 – 0.89)(P < 0.01) and reflux 
groups (OR 0.77 (95% CI 0.5 – 1.19) and the combined use of aspirin plus statin was 
associated with a lower risk of Barrett’s esophagus: compared to the dyspepsia-control (OR 
0.52 (95% CI 0.28 – 0.94) (P < 0.05) and compared to reflux-controls (OR 0.58 (95% CI 0.31 
– 0.95) (P < 0.05).  Metformin use was associated with a lower risk of Barrett’s esophagus 
when compared to the dyspepsia-controls but not the reflux-controls and beta-blockers were 
used less in the Barrett’s group than the reflux-controls but not the dyspepsia controls. In the 
unadjusted analysis, the use of angiotension converting enzyme inhibitors was associated 
with a reduced incidence of Barrett’s esophagus compared to both control groups. No 
medications were associated with an increased risk of Barrett’s esophagus. 
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Use of statins and aspirin  
Prior use of either aspirin or a statin for at least 6 months prior to index gastroscopy was 
associated with a reduced risk of Barrett’s esophagus. After adjustment for confounding 
factors, statin use was associated with an overall significant reduction in Barrett’s esophagus 
compared to dyspepsia-controls (adjusted odds ratio (aOR) 0.54 (95% confidence intervals 
0.34 – 0.87) (P < 0.01) and non-significant reduction compared to reflux-controls (aOR 0.74 
(95% CI 0.45 – 1.10) (table 3). There was no significant difference between statin use in the 
reflux and dyspepsia control groups and overall compared to all pooled controls prior statin 
use was associated with a reduced risk of Barrett’s esophagus (aOR 0.62 (95% CI 0.37 – 
0.93) (P < 0.01). Aspirin use was associated with consistent, but non-significant reduction in 
Barrett’s esophagus compared to all control groups (as shown in table 3).  
The combination of aspirin and a statin when taken for more than 6 months was associated 
with a consistent and significant reduction in the risk of Barrett’s esophagus: compared to 
dyspepsia-controls (aOR 0.39 (95% CI 0.19 – 0.86)), reflux-controls (aOR 0.47 (95% CI 0.22 
– 0.90)) and all controls (aOR 0.43 (95% CI 0.21 – 0.89))(all P < 0.01). In all cases the effect 
of combined aspirin and statin was greater than either alone.  
After adjustment for potential confounders including statin and aspirin use, no other 
medications or risk factors were found to have a significant association with Barrett’s 
esophagus.  The number of subjects using non-aspirin NSAIDS was too small to analyse 
separately.  
The vast majority of the current statin use (88%) was with simvastatin 40 mg once daily and 
no further attempt was made to examine the effects by statin dose, drug or pharmacological 
behaviour.  
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As shown in table 4, a longer duration of statin treatment or aspirin plus statin was associated 
with a lower risk of Barrett’s esophagus. This was seen compared to both the dyspepsia 
controls and the reflux controls. Statin use for more than 5 years was associated with a lower 
risk of Barrett’s esophagus (aOR 0.46 (0.13 – 1,28) in all controls, compared to 2 – 5 years 
(aOR 0.72 (0.40 – 1.15) or 6 months to 2 years (aOR 0.86 (0.51 – 1.46) (P < 0.05 for trend). 
Similarly the combined use of aspirin plus statin for 5 years was associated with a lower risk 
of Barrett’s esophagus (aOR 0.34 (0.05 – 1.34) compared to 2-5 years (0.61 (0.25 – 1.09) or 6 
months to 2 years (0.81 (0.24 – 1.56) when compared to all controls (P < 0.05 for trend). 
 
Meta-analysis 
Including the current study, 4 case-control studies were suitable for inclusion in the meta-
analysis. The pooled results included 1089 Barrett’s cases and 2085 controls, and 
demonstrated a significant inverse association between previous statin use and a new 
diagnosis of Barrett’s esophagus pooled unadjusted OR 0.68 (95% CI 0.58 – 0.796) (P < 
0.0001) (figure 1). A similar relationship was seen in the pooled adjusted OR 0.63 (95% CI 
0.51 -0.778)(P < 0.0001) (figure 2). Results were consistent across all studies with no 
heterogeneity (I 2 = 0) despite differing methodologies.  
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Discussion  
In this study we have demonstrated that regular use of statin, or the statin and aspirin 
combination in men is associated with a reduced incidence of the diagnosis of Barrett’s 
esophagus. There appeared to be a duration-response relationship with longer duration of 
treatment being associated with a greater degree of risk reduction and the combination of 
aspirin plus statin was always associated with a greater inverse association with risk of 
Barrett’s compared to either drug alone. Although aspirin use was common, as reported 
previously in this population, regular (at least once a week) use of NSAIDs and selective 
COX-2 inhibitors is much less common. Therefore, we cannot examine whether these effects 
of aspirin are generalizable to all cyclo-oxygenase inhibitors or only seen with low-dose 
aspirin used for circulatory diseases (16). 
Our data are limited to men and further studies are warranted in women. It is clear that there 
are important sex-related differences in the incidence and prognosis of Barrett’s esophagus. 
Whether this relates to life-style, adipose tissue distribution or metabolism remains unclear 
and hence further follow up studies in women are required. A similar male preponderance 
was seen in other similar studies (21,22). 
The main strengths of our study are the accurate and full records of medication exposure as 
reported previously (14,15,23) and the ability to correlate this with clearly defined 
endoscopic findings within the context of an adequately powered study. The main weakness, 
inherent in any observational study, is that of uncorrected bias. Although we have corrected 
for known and suspected confounders, it does remain possible that other factors are still 
influencing the results. Most specifically life-style factors related to a diagnosis of Barrett’s 
oeosphagus may be undetected; for example the greater use of circulatory disease treatments 
(statins and anti-platelets) could reflect a more active engagement in health promotion in the 
non-Barrett’s groups. In this study we did not specifically explore socioeconomic factors or 
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systematically assess current H pylori status. H pylori infection has a rather controversial 
relationship with gastroesophageal reflux and Barrett’s esophagus: decreased acid secretion 
associated with infection may be protective against acid-related reflux disease (4). The 
overall prevalence of H pylori infection in patients undergoing gastroscopy in our unit is less 
than 10% (Beales, unpublished) and although this is an extra variable to be considered, we 
feel this is unlikely to significantly affect the relationship between statin use and Barrett’s 
esophagus.  
The other main weakness of our study is the definition of an incident case of Barrett’s 
esophagus: we have used when this was first diagnosed endoscopically. Of course, the 
Barrett’s metaplastic change could have been present for some time preceding the 
gastroscopy or even statin treatment. We have attempted to minimise this potential bias by 
only including cases and controls having their first gastroscopy for dyspeptic symptoms. The 
issue of how long any Barrett’s segment has been present before discovery remains 
contentious and cannot be solved by either cross-sectional prevalence data or case-control 
studies such as the present study. However the similar case-control methodology has been 
widely employed to examine other risk factors for Barrett’s (24-26). 
 
Several individual studies (3-15,27) and 2 systematic reviews (that produced essentially 
identical results despite slightly different methodologies (16,17)) have reported that statin 
use, and particularly statin use combined with a cyclo-oxygenase inhibitor, is associated with 
a reduced incidence of esophageal adenocarcinoma. This has been reported in cohort studies 
and case-control studies of Barrett’s patients and population-based studies compared to 
population-based controls, although not all studies are in agreement (28). Within the 
progression to cancer it is not clear whether the effects of statin (and aspirin) are seen mainly 
at the points of development and maintenance of the Barrett’s segment or on preventing 
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progression to dysplasia and cancer. Whilst the cohort and case-control studies suggest statins 
and aspirin may prevent progression in an existing Barrett’s segment; the current study 
suggests that statins and aspirin may prevent the development of the Barrett’s segment as 
well. 
 
We used two separate control groups: erosive reflux and those with no significant endoscopic 
findings. We found a similar pattern of reduced risk of Barrett’s esophagus associated with 
statin use in both those with and without erosive reflux disease. This suggests that any effects 
of statins, or aspirin plus statins are not due to either prevention of reflux or development of 
erosive changes due to reflux (statins have well-recognised anti-inflammatory effects (29,30). 
We recognise that our dyspepsia-control group inevitably contains patients with non-erosive 
reflux disease, but do not feel this demonstrably weakens our hypothesis that statin treatment 
(with or without aspirin) may be associated with a reduced risk of Barrett’s esophagus, 
unrelated to any effects on esophageal acid exposure or the severity of endoscopic mucosal 
changes. 
 
Perhaps due to the difficulties inherent in studying this area, there are relatively few studies 
examining prescribed and non-prescribed medications as risk factors for Barrett’s esophagus 
compared to the number of studies examining esophageal cancer (16,17,20).  Statin use as a 
risk factor for Barrett’s specifically been examined in 3 other studies.  
 
The most novel aspect of our current study is the meta-analysis of all the available data and 
this shows a significant and consistent inverse association between statin use and a new-
diagnosis of Barrett’s oesophagus.  Regular statin use is associated with a 37% reduction in 
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the incidence of new diagnoses of Barrett’s esophagus. This finding is consistent across the 4 
studies, despite slightly different methods. 
Nguyen et al (21) examined statin use from prescribing records and compared Barrett’s cases 
to both non-Barrett’s cases referred for diagnostic gastroscopy and a population-based cohort 
referred for colonoscopic cancer screening that had a gastroscopy purely for research 
purposes. In this, overwhelmingly male, cohort statin use was associated with a lower risk of 
Barrett’s esophagus (aOR 0.57 (95% CI (0.38 – 0.87) and as in the current study a longer 
duration of statin use was associated with lower risk of Barrett’s esophagus. Interestingly, in 
light of the results presented in our current study, the inverse association between statin use 
and a new diagnosis of Barrett’s esophagus was more pronounced in those concurrently using 
aspirin (aOR 0.45 (95% CI 0.20 - 0.99) than those not using aspirin (aOR 0.73 (95% CI 0.32 
– 1.65).   A further case-control study using Barrett’s-negative endoscopy patients as 
controls, including 242 male Barrett’s patients, showed that statins were associated with a 
reduced rate of new diagnoses of Barrett’s esophagus (aOR 0.53 (95% CI 0.35 – 0.81) (32). 
Interpretation of the results from this latter study are complicated by the retrospective, chart-
review design and the absence of data on body habitus, smoking and other medications taken 
(32). One further study has attempted to examine the effects of the use of statins on the 
incidence of Barrett’s esophagus. Omer et al reported that statin use was associated with a 
reduced rate of new diagnoses of Barrett’s esophagus in the initial univariate analysis (OR 
0.72 (95% CI 0.52 – 0.98)) but the statistical significance of this finding was not confirmed in 
the multivariate analysis (aOR 0.79 (95% CI 0.54 – 1.2) (22). Inaccuracies may be inherent in 
this study due to the purely retrospective nature of the data collection, lack of data on 
initiation of, or duration of statin use, relying on tertiary care centre endoscopy controls and 
the lack of matching in between cases and controls (there were significantly more females in 
the control group).   
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Although Nguyen et al (21) did stratify the effect of statin by aspirin use, the other studies did 
not. The available data on the effect of aspirin alone on the incidence of Barrett’s esophagus 
are contradictory: an inverse association between aspirin use and Barrett’s esophagus has 
been reported (22) but 2 other studies failed to find such an association (32,33).  
 
The putative mechanisms of the effects of statins and aspirin in possibly preventing the 
development and establishment of Barrett’s remain subject to conjecture. Experimentally 
statins inhibit proliferation and induce apoptosis in Barrett’s cell lines and these effects are 
enhanced in an additive manner in combination with inhibition of the cyclo-oxygenase-2 
pathway (10,11). Over-expression of COX-2 in Barrett’s mucosa has been reported, and 
experimentally (34), and in clinical studies beneficial effects of COX-inhibitors on 
progression to cancer have been reported (13,16,35-37). Thus it is possible that statin and 
aspirin impair survival of the Barrett’s clone at a very early stage and so impair establishment 
of a mature Barrett’s segment. There are several putative mechanisms that could also be 
involved: aspirin reduced NF-kB signalling (38), which may in turn alter the nuclear 
transcription factor milieu that seems to be important in driving the development of Barrett’s 
(39) and statins may influence the secretion of adipokines (such as adiponectin and leptin) 
which in term seem to influence the behaviour of metaplastic Barrett’s epithelial cells (40-
44). 
 
In conclusion, we have shown that statin use in men is associated with a significantly reduced 
rate of new diagnosis of Barrett’s esophagus, this effect is more pronounced in concurrent 
aspirin users and there is greater effect with longer use of statins alone or combined with 
aspirin. Meta-analysis of pooled data confirms a significant reduction (37%) in the incidence 
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of Barrett’s esophagus in statin users, with no heterogeneity in the results, despite 
differencing methodologies and control groups. Statins may protect against the development 
of Barrett’s esophagus and this may contribute to the reduced risk of esophageal cancer seen 
in statin users in population studies. Further studies are required to determine if the 
relationship is causal and explore the mechanisms of action of statins on the esophageal 
mucosa. 
 
. 
. 
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Table 1. Basic demographic data 
 
 
 
 
 Barrett’s 
eesophagus 
Dyspepsia 
controls 
Reflux controls 
N 134 268 268 
Mean Age 
(±SD) 
65.8 (13.8) 69.1 (11.3) 65.5 (11.4) 
Smokers    
Current (%) 27 (20.1) 40 (14.9) 37 (13.8) 
Ex- (%) 30 (22.4) 46 (17.1) 51 (19.0) 
BMI (kg/m2)    
<25 (%) 37 (27.6) 86 (32.0) 89 (33.2) 
25-30 (%) 64 (47.7) 115 (42.9) 107 (39.9) 
>30 (%) 47 (35.1) 67 (25) 72 (26.8) 
Waist 
Circumference 
   
<93 cm (%) 12 (8.9) 48 (17.9) 40 (14.9) 
93.1-102 cm(%) 58 (43.3) 113 (42.1) 107 (39.9) 
>102.1 cm (%) 64 (47.8) 107 (39.9) 121 (45.1) 
Alcohol    
Never (%) 32 (23.9) 86 (32.1) 62 (23.1) 
< 10 u/wk (%) 58 (43.3) 104 (38.8) 112 (41.8) 
> 19 u/wk (%) 44 (32.9) 78 (29.1) 94 (35.1) 
 
There were no significant differences in any basic demographic factor between any of 
the groups (all P > 0.05)  
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 Barrett’s 
esophagus 
(134) 
Dyspepsia 
controls 
(268) 
OR 
Barrett’s 
vs. 
Dyspepsia 
(95% CI) 
Reflux 
controls 
(268) 
OR 
Barrett’s 
vs. 
Reflux 
(95% CI) 
 N (%) N (%)  N (%)  
Statin 48 (35.8) 131 (48.8) 0.58 (0.38 
- 0.89)** 
112 (41.7) 0.77 (0.50 
- 1.19) 
Aspirin 29 (21.6) 66 (24.6) 0.84 (0.51 
- 1.38) 
68 (25.3) 0.81 (0.40 
- 1.32) 
Statin and 
aspirin 
18 (13.4) 60 (22.3) 0.53 (0.24 
- 0.94)* 
61 (22.8) 0.56 (0.31 
- 0.95)* 
CCM 17 (12.7) 36 (13.4) 0.94 (0.49 
-1.72) 
38 (14.1) 0.87 (0.46 
– 1.61) 
ACE-I 18 (13.4) 92 (34.4) 0.29 (0.17 
– 0.51)** 
75 (27.9) 0.40 (0.22 
– 0.69)** 
ARB 6 (4.47) 15 (16.8) 0.79 (0.27 
- 2.00) 
14 (5.2) 0.85 (0.29 
– 2.23) 
Beta-blocker 18 (13.4) 45 (16.8) 0.77 (0.41 
– 1.77) 
64 (23.8) 0.49 (0.27 
– 0.86)* 
Insulin 4 (2.9) 12 (4.47) 0.65 (0.18 
- 2.00) 
34 (12.7) 0.56 (0.50 
– 1.66) 
Metformin 10 (7.4) 51 (19.0) 0.32 (0.16 
- 0.68)** 
10 (3.7) 0.55 (0.25 
– 1.14) 
Other diabetic 
meds 
4 (2.9) 24 (8.9)  0.32 (0.23 
-2.89) 
20 (7.4) 0.79 (0.21 
– 2.52) 
NSAIDs 5 (3.7) 9 (3.3) 1.15 (0.33 
– 3.4) 
24 (8.9) 0.48 (0.15 
– 1.16) 
Inhaled beta2-
agonists 
13 (0.9) 27 (10.1) 0.93 (0.44 
– 1.89) 
37 (13.8) 0.65 (0.32 
– 1.25) 
Inhaled steroids 14 (10.4) 33 (12.3) 0.80 (0.43 
- 1.54) 
27 (10.0) 1.00 (0.49 
– 1.97) 
Theophylline 0 (0) 3 (1.1) - 0 (0) - 
Alpha blocker 10 (7.5) 30 (11.1) 0.64 (0.29 
- 1.33) 
31 (11.5) 0.62 (0.28 
– 1.18) 
Anti-cholinergic 
meds 
8 (6.0) 15 (5.6) 1.08 (0.41 
- 2.57) 
20 (7.4) 0.79 (0.32 
– 1.81) 
Bisphosphonates 2 (1.5) 6 (2.23) 0.66 (0.09 
- 3.17) 
0 (0) - 
      
 
Table 2. Medication consumption 
CCM, calcium channel modulator: ACE-I, angiotensin converting enzyme inhibitor: ARB, 
angiotensin receptor blocker: NSAIDs, non-aspirin non-steroidal anti-inflammatory drugs 
including non-selective and COX-2 selective agents, anti-cholinergic medications includes 
any with anti-cholinergic pharmacodynamics effects including inhaled anti-cholinergic drugs 
or tricyclic antidepressants. 
* P < 0.05, ** P < 0.01 
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Table 3. Adjusted Odds ratios for use of statin and/or aspirin for at least 6 months prior 
to the diagnosis of Barrett’s esophagus compared to dyspepsia controls or erosive reflux 
controls. 
 
 Barrett’s vs 
dyspepsia controls 
(95% CI) 
Barrett’s versus 
reflux controls 
(95% CI) 
Barrett’s versus all 
controls 
(95% CI) 
Statin 0.54 (0.34 – 0.87)** 0.74 (0.45 -1.10) 0.62 (0.37-0.93)** 
Aspirin 0.80 (0.51 – 1.30) 0.75 (0.46 – 1.19) 0.77 (0.46 – 1.14) 
Statin + aspirin 0.39 (0.19 – 0.86)** 0.47 (0.22 – 0.90)** 0.43 (0.21 – 0.89)** 
 
 
** P < 0.01  
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 Barrett’s vs non-
reflux controls 
(95% CI) 
Barrett’s versus 
reflux controls 
(95% CI) 
Barrett’s versus all 
controls 
(95% CI) 
Duration of statin 
use 
   
6 months – 2 years 
(%) 
 
0.79 (0.44 -1.42) 0.92 (0.51 – 1.65) 0.86 (0.51 – 1.46) 
2 – 5 years (%) 
 
0.56 (0.33 – 0.95) 0.87 (0.51 -1.49) 0.72 (0.40 – 1.15) 
5 years + (%) 0.45 (0.12 -1.37) 0.48 (0.11 – 1.58) 0.46 (0.13 – 1.28) 
Duration of aspirin 
used 
   
6 months – 2 years 
(%) 
 
1.15 (0.47 – 2.7) 0.95 (0.39 – 2.17)  1.02 (0.46 – 2.19) 
2 – 5 years (%) 
 
0.78 (0.39 – 1.4) 0.78 (0.49 – 1.44) 0.78 (0.42 – 1.36) 
5 years + (%) 0.70 (0.12 – 1.67) 0.69 (0.18 – 2.16)  0.69) (0.20 – 1.94) 
Duration of Statin 
plus aspirin use 
   
6 months – 2 years 
(%) 
 
1.04 (0.34 – 2.63) 0.66 (0.23 – 1.69)  0.81 (0.24 – 1.56) 
2 – 5 years (%) 
 
0.77 (0.32 – 1.72) 0.53 (0.25 – 1.19) 0.61 (0.25 – 1.09) 
5 years + (%) 0.30 (0.06 – 1.60) 0.39 (0.02 – 0.85) 0.34 (0.05 – 1.34) 
 
 
Table 4. Adjusted odds ratios for the use of statin and / or aspirin prior to the diagnosis 
of Barrett’s oesophagus compared to all pooled (dyspepsia and reflux) controls 
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Figure legends 
 
Figure 1 
 
Pooled unadjusted odds ratio for studies examining the association of statin use and incidence 
of Barrett’s esophagus 
 
 
 
 
Figure 2 
 
Pooled adjusted odds ratio for studies examining the association of statin use and incidence of 
Barrett’s esophagus   
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